3 results match your criteria: "Stuttgart and University Tuebingen[Affiliation]"
Cell Physiol Biochem
May 2016
Dr Margarete Fischer-Bosch-Institute of Clinical Pharmacology, Stuttgart and University Tuebingen, Tuebingen, Germany.
Background/aims: Inhibition of p38 mitogen-activated protein kinase (p38 MAPK) is promising for the treatment of inflammatory disorders, however, the efficacy of p38 MAPK inhibitors in clinical trials is limited so far. Since functional sensitivity of p38 MAPK is commonly predicted by preclinical species, we systematically investigated interspecies differences including human tissue.
Methods: Ex vivo test models were established using whole blood and primary cells from different species such as mice, rats, pigs and humans to compare LPS-induced TNF-α inhibition of four different p38 MAPK reference inhibitors SB 203580, BIRB-796, Pamapimod, and a Losmapimod analogue as well as a proprietary imidazole-based p38 MAPK Inhibitor.
Eur J Hum Genet
April 2014
1] Birmingham Women's Hospital-West Midlands Regional Genetics Laboratory, Birmingham, UK [2] Department of Medical Genetics, University of Cambridge, Cambridge, UK.
Breast Cancer Res Treat
November 2009
Dr. Margarete Fischer-Bosch-Institute of Clinical Pharmacology, Stuttgart and University Tuebingen, Auerbachstrasse 112, 70376, Stuttgart, Germany.
Endocrine breast cancer treatment relies on estrogen receptor alpha (ERalpha) assessment, which does not predict response in all cases. We investigated whether ESR1 promoter C driven (ESR1_C) gene expression may shed light on endocrine responsiveness. We investigated archived tumor tissues of 211 patients.
View Article and Find Full Text PDF